Resources

Advisers' Recommended Reading

FDA: Doctors Should Look For Alternatives To Blood Clot Drug The FDA posted a letter to its Web site on Wednesday from Celgene Corp. warning users of blood-clot busting drug Innohep that new findings suggest the drug may lead to death in the elderly.
Plavix Blood Thinner Effectiveness Influenced By Gene Variants Two studies of heart patients showed that the blood thinner clopidogrel (brand name Plavix) was less effective in carriers of certain variants of a gene known to affect how the drug prevents blood clots than non-carriers.
This year’s most interesting hematology stories Two articles concerning anticoagulants are worth emphasizing. In February, Kenneth Bauer, MD, editorialized on a new oral anti-Factor Xa agent, rivaroxaban (Xarelto, Bayer/Ortho-McNeil). That it soon may replace parenteral anticoagulants in acute situations, as well as warfarin in more chronic conditions seems likely.
West Penn Testing Possible Warfarin Replacement “Rivaroxaban shows great promise as a replacement for warfarin, a medication that has been the only oral anticoagulant for the last 60 years, and can be difficult to dose correctly,” said Dr. Margaret Kennedy who is the principal investigator in the two trials.

ThrombosisManagement CME Registry of federally and privately supported clinical trials conducted in the United States and around the world
ClinicalTrialResults.org Registry of federally and privately supported clinical trials conducted in the United States and around the world
ClinicalTrials.gov Registry of federally and privately supported clinical trials conducted in the United States and around the world